Lymphoma Hub Satellite Symposium 2021: Summary and roundtable discussion

On Friday, June 18, 2021, at the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub hosted a virtual satellite symposium on the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia (CLL).

The symposium brought together a panel of international experts, who gave their opinion on four distinct cases of patients with primary refractory diffuse large B-cell lymphoma, early relapsing follicular lymphoma, TP53-mutated mantle cell lymphoma, and ibrutinib-resistant CLL. Click to see the presentations by Andrew Davies, Loretta J. Nastoupil, Steven Le Gouill, and Francesc Bosch.

Below you can find the articles published by the Lymphoma Hub in the lead-up to the symposium:

• The management of toxicities associated with targeted agents in CLL
• Targeted agents for patients with follicular lymphoma
• Treatment landscape for mantle cell lymphoma: An update

The symposium concluded with an exciting roundtable discussion mediated by Lymphoma Hub Chair Gilles Salles. You can watch the discussion below, where the panelists answered questions submitted by the audience.

In the lead-up to the virtual symposium, the Lymphoma Hub conducted a series of Twitter polls to gain insight into the audience’s understanding of, and interests within, the field of relapsed/refractory lymphoma (Figure 1).

Figure 1. Results of the Lymphoma Hub Satellite Symposium Twitter polls 

BTKi, Bruton’s tyrosine kinase inhibitor; CAR-T, chimeric antigen receptor T-cell therapy; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; PI3Ki, phosphoinositide 3-kinase inhibitor; R/R, relapsed/refractory.

The Lymphoma Hub would like to thank the symposium speakers and attendees for an engaging event!